Chiglitazar, a PPAR complete agonist, is a new oral drug approved by China’s national medical products administration for T2D treatment in 2021; it can activate three subunits of PPAR (α, γ, and δ) [38,39]. The gene discussed is PPARA; the disease is type 2 diabetes mellitus.